Several promising therapies for CKD, including apoptosis signal-regulating kinase 1 (ASK1) inhibitor, endothelin receptor antagonist, phosphodiesterase inhibitor, Janus kinases (JAK)1/2 inhibitor and nuclear factor erythroid 2-related factor 2 (Nrf2) activator have been undergoing clinical trials [33,34,35,36,37]. The gene discussed is NFE2L2; the disease is chronic kidney disease.